Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

SirtexMedicalStudy

More Like This

PR Newswire associated0

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

PR Newswire associated0

Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres

PR Newswire associated0

Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System

HistoSonics’ Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

PR Newswire associated0

Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member